a role in the pathogenesis of ITP. 3, 4 In the present case, however, there was no sign of GVHD throughout the clinical course. The platelet count drastically decreased 2 weeks after the influenza vaccination, possibly suggesting that the influenza vaccination caused this complication. Patients with acute ITP usually have a precedent infection: ITP characteristically appears 7-10 days after the primary symptoms of the infection. Common preceding infections are rubella, Epstein-Barr virus, Varicella zoster virus and influenza virus infections, although non-specific viral infections still predominate. Acute ITP may also occur after vaccination. 5, 6 Antibodies responsible for the clearance of virus antigens may cross-react with antigens naturally present on platelets. Autoantibodies, predominantly IgM, to platelet surface antigen were transiently detected in a majority of the children with acute ITP. 7 Disappearance of IgM antibodies from the circulation may explain the self-limiting nature of acute ITP; spontaneous remissions occur in a majority of patients. Machado et al., in their article, did not describe the adverse effects of influenza vaccine. There were several reports of other adverse effects, including influenza-vaccine-associated Guillan-Barre syndrome 8 and a transient production of autoantibodies in patients with SLE. 9 Although we appreciate the benefit of influenza vaccination for BMT recipients, since those patients may be in an immunestimulated condition, we should carefully monitor the inmmunological adverse effects.
REPLY
Reply to Ikegame et al. Ikegame et al. reported a case of idiopathic thrombocytopenic purpura (ITP) in a BMT recipient and attributed this complication to influenza vaccination. However, this association should be interpreted with caution since several factors, as mentioned by the authors, have been linked to the occurrence of ITP, which is still called 'idiopathic' because the cause remains uncertain.
In the normal population and in other high-risk groups, side effects of influenza vaccination are generally mild and observed up to 48 h of vaccination. Local reactions (soreness at the vaccination site) can affect 10-64% of the subjects but rarely interfere with daily activities. 1 Systemic reactions like fever, malaise, myalgia, headache, etc, are less frequent. Recent placebo-controlled studies including persons with asthma, 2 the elderly 3 and healthy young adults 4 did not show higher rates of systemic reactions among vaccinated in comparison to the placebo group. Non-controlled studies have reported systemic reactions in 10-25% of the patients. 1 With regard to late complications (those occurring between 10 and 14 days after vaccination), more attention has been paid to the occurrence of Guillain-Barre Syndrome (GBS) that was associated to the 1976 swine influenza vaccine. 1 Evidence for a causal relation of GBS with the following influenza vaccines is unclear and the rarity of the disease (10-20 annual cases of GBS/1 million adults) further limits epidemiological studies due to the huge number of subjects that should be included. In BMT recipients, influenza vaccination has been recommended annually, and widely used. The vaccine is recommended to patients transplanted longer than 6 months due to poor serological responses before this period, and not for safety reasons. 5 As 1993, when the reimmunization program after BMT was started, we have not observed any severe side effect that could be attributed to influenza vaccination. This observation includes the patients enrolled in our study of clinical efficacy of influenza vaccine, 6 It is important to stress that the association of ITP with influenza vaccination is supported only by individual case reports, similar to the case reported by Ikegame et al. One could argue that in the scenario of a haploidentical transplant, ITP could be triggered by the intense antigenic stimulation and/or by subclinical reactivation of latent infections, which were not ruled out in this case.
Although carefully monitoring for adverse effects after any recommended vaccine post BMT is desirable, the benefit of influenza vaccination in preventing serious illness, hospitalization and death considerably outweigh the possible risk of any adverse effect. In times of avian influenza threatening and worldwide efforts to increase compliance to vaccination, reports encouraging a positive attitude toward influenza vaccination are certainly welcome.
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